Share on

Global Cancer Immunotherapy Market Size, Share, Trends, Growth, COVID-19 Analysis Report – Segmented By Type of Therapies, Area of Therapy (Blood Cancer, Prostate Cancer, Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer & Other Minor Areas) and Region - Industry Forecast (2022 to 2027).

Published: January, 2022
ID: 1336
Pages: 182
Formats: report pdf report excel report power bi report ppt

Cancer Immunotherapy Market Size (2022 to 2027)

As per our report, the global cancer immunotherapy market is forecasted to grow at a CAGR of 12.52% from 2022 to 2027. This market is predicted to be worth USD 178.5 billion by 2027 from USD 99.02 billion in 2022.

Immunotherapy, also known as biologic therapy, can be performed in two ways. That is by stimulating one’s immune system to fight against the disease by attacking defective cancer cells and giving immune system constituents from outside, such as synthetic proteins, into the body to fight against the disease. It is performed to treat cancer patients for a long time, even when doctors do not thoroughly understand the immune system. Immunotherapy is a treatment option that uses certain parts of an immune system to fight against various diseases such as cancer.

Cancer immunotherapy is a therapy used to treat various cancer diseases involving stimulation and suppression of the immune system. It is made of white blood cells, organs, and tissue of the lymphatic system. Several companies are investing massive amounts in the treatment of cancer. U.S. food and administration has approved 32 immunotherapies to treat 20 cancer types, including cell-based immunotherapies, immunomodulators, BCG vaccines, targeted therapies, and oncotic viruses.

Impact of COVID-19 on the cancer immunotherapy market:

COVID-19 has a positive impact on the healthcare sector. World health organization announced COVID-19 as a pandemic on March 11, 2020. During the first half of 2020, the cancer immunotherapy market was slightly reduced due to the lockdown restrictions and ban on travel. There was an increase in the cancer patient rate, but the world was focused on fighting against coronavirus, and many cancer treatments have been postponed. As there is a high risk for cancer patients due to COVID 19, they need to stay home. The treatment procedures for the cancer patients were resumed in the last months with the preventive measures as it is mandatory to give continuous treatment. The market shares are expected to grab the highest growth rate by 2021. 

Multiple therapeutic regimens are being followed across various countries to develop a reliable cancer treatment. Immunotherapy is a cancer treatment that boosts the human immune system to fight against cancer cells. But cancer treatment therapies have been stopped and postponed by various hospitals worldwide due to the sudden outburst of the COVID-19 pandemic. In addition, many countries have been impacted negatively by coronavirus. Therefore, no activities related to cancer therapies have been done due to the unavailability of doctors and medical centers, but cancer patients need to monitor their conditions regularly. This is expected to result in industry growth over the forecast period.


The growing occurrence of cancer, the rising number of R & D, and technological developments in treatment options are majorly fuelling the global cancer immunotherapy market.

Cancer has now become one of the leading causes of death worldwide. According to the statistics published by the World Health Organization (WHO), an estimated 9.6 million died of cancer in 2018 also found tobacco was the leading risk factor for cancer and recorded 22% of the responsibility for cancer deaths in 2018. The noticed increasing prevalence of cancer is estimated to favor the growth of the global cancer immunotherapy market.

Additionally, the global cancer immunotherapy is fuelled by the high efficacy of immunotherapy compared to other treatments, fewer side effects associated with cancer immunotherapy, and reduced chance of cancer recurrence. Other notable drivers expanding the market size are technological advances in clinical therapies, increased R&Ds for cancer treatment, and the specificity and efficacy of cancer immunotherapy to treat a wide range of cancers.

The rising adoption of advanced therapeutics for cancer and growing implementation in the healthcare sector to treat cancer diseases is also supporting the growth of the global cancer immunotherapy market. Also, public organizations are focusing on investment in Research and development activities to develop new cancer immunotherapy. CAR –T cell therapy development is also propelling the market growth.


The primary factor restraining the market's growth is various cancer-like Melanoma shows, resistance to chemotherapy and radiation therapies, the Cost of cancer therapies, and limited information on cancer immunobiology. Furthermore, the high competition in the product development cycle is restraining the market's growth. Depending upon the cancer types and patients, it is complicated to develop a new drug with high quality, which impedes the market's demand. Also, a lack of skilled professionals and awareness among the people hamper the market growth.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Type of Therapies, Area of therapy, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa


This market research report on the global cancer immunotherapy market has been segmented and sub-segmented based on the type of therapies, treatment area, and region.

Cancer Immunotherapy Market – By Type of Therapies:

  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies

Based on the type of therapies, the monoclonal antibodies segment is expected to dominate the global cancer immunotherapy market during the forecast period and account leading share in 2020. The primary trend driving the market is the rise in monoclonal antibodies to treat various cancers like breast cancer, lymphoma, lung cancer, brain cancer, cervical cancer, and others. Because of the high drug specificity toward cancer cells, this is mainly attributed to the technological superiority of this approach. These drugs are designed to identify and create a targeted immune response to cancer cells based on their proteins on the cell surface and forgo normal cells.

The monoclonal antibody segment had the most significant growth in the previous year due to high R & D investment in R&D. Some monoclonal antibodies are used for the targeted treatment of cancer. There are various types of monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies. Now AbbVie product Adalimumab monoclonal antibody was the highest selling product in 2019.

Cancer Immunotherapy Market – By Area of Therapy:

Based on therapy, there is increasing use of cancer immunotherapy for melanoma therapy. Melanoma segment growth can be directly linked to new product development, many FDA approvals, and extensive research and development in this area. The U.S. FDA has recently approved three melanoma treatment checkpoint inhibitors, three cytokine therapies, and one oncolytic virus therapy.

Lung cancers had the most substantial market revenue in 2019. In 2020, the U.S. food and drug administration approved Tabrecta (Capmatinib) to treat non-small cell lung cancer. Melanoma is the fastest-growing segment due to advanced new development in the cancer immunotherapy market.

Cancer Immunotherapy Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

In 2021, North America held the largest share of the global cancer immunotherapy market. Increasing disease incidence, and increasing accessibility to modern therapy, combined with a growing senior population, lead to regional market development. The North American market is further growing due to the region's highest cancer-caused population, aged population, and modern lifestyle. In addition, there is a noticeable increase in the biotechnology companies in the U.S. compared to the previous year, driving the cancer immunotherapy market in North America.

Europe's global cancer immunotherapy market has significant growth due to advanced technology and various clinical trials.

The Asia Pacific is expected to experience the fastest growth throughout the forecast period. Chinese and Japan are introducing new and sophisticated immunotherapy medications. These countries have many current clinical trials for new drug molecules, alternative treatments, and FDA approvals. Approval of new treatment drugs in China and Japan is improving the tumor treatment acceptance of immunotherapy.

Recently, the food and drug administration approved new technologies and implementation in China and Japan to treat small-cell lung cancer. India is driving the cancer immunotherapy market due to the vast population and genetic variation. The recent FDA approval and new drug introduction are propelling the market growth.


Companies leading the global cancer immunotherapy market profiled in the report are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co, Celgene Corp, and Immunomedics.


  • In 2019, Roche Holding AG approved launching its new atezolizumab cancer immunotherapy in India. It is beneficial to treat small cell lung cancer patients with chemotherapy. Also, the company wants to expand its developed market in India to treat cancer disorders. 
  • In 2019, Merck introduced new cancer immunotherapy, Keytruda, with Pfizer Inlyta to minimize kidney cancer disease risk. The drug will give a high response rate and improved progression compared to chemotherapy treatment. 
  • In March 2020, Forty-seven was acquired by Gilead Life sciences. This acquisition has helped Gilead expand its global cancer immunotherapy treatment for various diseases. Forty-seven has lead product magrolimab, and it is a monoclonal antibody used for the treatment of acute myeloid leukemia and B-cell lymphoma.
  • In October 2015, the FDA approved the first oncolytic virus therapy known as Talimogene laherparepvec (T-VEC or Imlygic). The vaccine treats metastatic melanoma that cannot be eliminated by surgery.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample